Noxopharm White Paper

NOXOPHARM L IMITED White Paper 10 Veyonda® – DARRT program continued DARRT-1 A Phase 1 study which combined Veyonda with radiotherapy (RT) in patients with metastatic castration-resistant prostate cancer (mCRPC) that had progressed on all available treatments. Patients received palliative (low-dose) RT with Veyonda. Notably, DARRT-1 patients had such advanced cancer that RT treatment was palliative, that is, intended only to reduce pain and other symptoms in order to improve quality of life for a limited period. The results of DARRT-1 were highly encouraging. • Veyonda/low-dose RT treatment was safe and well-tolerated. • Disease progression either stopped (stable disease) or improved (partial response) in the majority of patients that were evaluable at 12 week and 24 week follow up. • A majority of patients achieved a clinically meaningful pain response at 12 and at 24 weeks. Notably some patients were pain-free at 24 weeks. • PSA levels dropped by over 50% in a number of patients at 12 weeks. This effect was found to persist for most of those individuals at 24 weeks. PSA (prostate specific antigen) in cancer therapy is an indicator of disease activity. • An abscopal effect was noted in 4 patients. In these patients, both the irradiated tumour and tumours outside of the radiation field shrank. DARRT-2 A Phase 1b/2a Multicenter Study of NOX66 and External Beam Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Other Solid Tumors. DARRT-2 will aim to recruit patients who have progressed on first or later lines of therapy. Veyonda will be delivered with RT to patients with mCRPC and patients with other solid tumours, specifically breast and lung cancer. This study is being prepared for sites in North America, Europe, and Australia. The first patient is expected to be enrolled in Q3 2021. The aim is to ensure enrolment is advancing well by the end of Q1 2022.